Daewoong Pharmaceutical Receives Approval for Phase 1/3 Clinical Trial Plan of 'Pexuprazan' in China
[Asia Economy Reporter Oh Ju-yeon] Daewoong Pharmaceutical announced on the 30th that the Phase 1/3 clinical trial plan for the gastroesophageal reflux disease treatment 'Pexuprazan' has been approved by China's NMPA.
Hot Picks Today
!["Not Everyone Can Afford This: Inside the World of the True Top 0.1% [Luxury World]"](https://cwcontent.asiae.co.kr/asiaresize/93/2026051507261063923_1778797570.png)
"Not Everyone Can Afford This: Inside the World of the True Top 0.1% [Luxury World]"
- While All Eyes Were on Samsung and Hynix, This Company Surged 50% to New Highs in Four Days [Weekend Money]
- "We're Now Earning 10 Million Won a Month"... Semiconductor Boom Drives Performance Bonuses at Major Electronic Component Firms
- "I'm No Longer the Center?"... Even the World's Top Sniper Sidelined in the Era of Drones
- "Target Price Set at 970,000 Won"... Top Investors Already Watching, Only an 'Uptrend' Remains [Weekend Money]
The company expressed expectations that "the efficacy and safety of Pexuprazan administration can be confirmed in patients with erosive gastroesophageal reflux disease."
This content was produced with the assistance of AI translation services.
© The Asia Business Daily(www.asiae.co.kr). All rights reserved.
